RACHEL REAUME: Open Payments
NPI 1144787615 · MONROE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,429 in 68 payments from 14 companies in 2025. Trend: 2023 $1,000 · 2024 $823 · 2025 $1,429
Food & beverage: $1,329Education: $99
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 16 | $447 |
| ABBVIE INC. | 25 | $391 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $161 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $110 |
| Madrigal Pharmaceuticals | 2 | $78 |
| Ardelyx, Inc. | 3 | $54 |
| Aimmune Therapeutics, Inc. | 3 | $53 |
| PFIZER INC. | 1 | $29 |
| Intercept Pharmaceuticals, Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $28 |
Products named: TREMFYA, SKYRIZI, ENTYVIO, XIFAXAN, REZDIFFRA, LINZESS, RINVOQ, IBSRELA.
Industry payments across MI — which companies pay providers there.
